

Anti-PDCD1/PD-1/CD279 Antibody (Nivolumab)

Introduction

Nivolumab is a humanized IgG4 antibody inhibitor of PD-1 used in the study of advanced (metastatic) non-small cell lung cancer.

Product parameters

Alternative Names	BMS-936558, MDX-1106
Target Accession	Q15116
Target	PDCD1 / PD-1 / CD279
CAS number	946414-94-4
Molecular Weight	145.24 kDa
Host	CHO
Reactivity	Human, Cynomolgus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human PD-1 His at 2 ug/mL can bind Anti-PDCD1/PD-1/CD279 Antibody (Nivolumab), EC50=0.007274 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

